

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/722,061	11/25/2003	Robert Karlsson	740073.462	4156	
500 7590 05/17/2007 SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE			EXAM	EXAMINER	
			LAM, ANN Y		
	SUITE 5400 SEATTLE, WA 98104		ART UNIT	PAPER NUMBER	
 ,			1641		
		•			
	•		MAIL DATE	DELIVERY MODE	
			05/17/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/722,061	KARLSSON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ann Y. Lam	1641				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR I WHICHEVER IS LONGER, FROM THE MAILI - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicat - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, b Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS COMMUNION CFR 1.136(a). In no event, however, may a retion. Properties of the propert	CATION. eply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed or	i <u>05 March 2007</u> .					
2a) This action is FINAL . 2b)	This action is FINAL . 2b) This action is non-final.					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims		·				
4)⊠ Claim(s) <u>1,2,5-8,10,12-19 and 35</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>1,2,5-8,10,12-19 and 35</u> is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Ex	aminer					
10)⊠ The drawing(s) filed on <u>25 November 2003</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
1.⊠ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	·	Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date. 20070511. Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

DETAILED ACTION

Claim Objections

Claims 1-2, 5-8 and 15 are objected to because of the following informalities.

The limitation "an analyte" (in line 2 of claim 1) and the limitation "a reference analyte" (in line 5 of claim 1) should be designated as —a first analyte—and —a second, reference analyte—, or in some similar manner so that it is clear as to what "the analyte" refers (in claim 1 and the subsequent dependent claims). The designation (e.g., —the first analyte—, and —the second, reference analyte—) should be made in the dependent claims listed above as well. While Examiner understands that "the analyte" is intended to be distinct from "the reference analyte", a different designation such as the example above would clarify the claims.

Also in claim 1, line 20, after "determining", Applicants should add –from a label-free detection technique--. While it is understood that Applicants intend to limit the claimed invention to those involving label-free detection techniques, there are several detection steps (one in the step of "monitoring" and at least one more in the step of "determining", that is after increasing the concentration of one of the analytes that has the faster dissociation phase), and thus adding the language suggested above would more clearly indicate that the determining step is also based on a label-free detection technique. Otherwise, the determining step could be interpreted to encompass detection techniques that use labels.

Art Unit: 1641

Moreover, in claim 1, line 23, after "wherein", Applicants should add –an influence in which--. While it is understood that Applicants intend for the correlation in the wherein clause to be referring to the influence recited in line 20, adding the suggested language would clarify that the correlation in the wherein clause is the influence that is determined in the step in line 20. Otherwise, the wherein clause could be simply interpreted to be a mere recitation of a correlation and the determining step in line 20 could be interpreted to be any kind of influences.

Appropriate correction is required.

Drawings

The drawings are objected to because the unlabeled binding curve in figure 8 should be labeled. (The brief description of figure 8 describes the drawing to be an overlay sensorgram with five superposed binding curves for the binding to a protein kinase of four inhibitors A-D and ATP. However in the drawing of figure 8, only the curves for A-D are labeled. It appears that the unlabeled binding curve should be labeled "ATP".) Also in figure 9, the unlabeled binding curve should be labeled. (The brief description of figure 9 describes the drawing to be an overlay sensorgram with four superposed binding curves for the competing binding to a protein kinase of an inhibitor A and ATP at increasing concentrations of ATP. However in the drawing of figure 9, only three of the binding curves are labeled. The fourth binding curve has a line drawn to it but is not labeled, and it appears that it should be labeled like the other binding curves.)

Art Unit: 1641

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Allowable Subject Matter

Claims 1-2, 5-8, 10, 12-19 and 35 are allowed.

The following is a statement of reasons for the indication of allowable subject matter: the prior art does not teach or suggest a method of monitoring by a label-free detection technique a dissociation phase of a mixture of two analytes to obtain a dissociation phase binding curve and increasing the concentration of the analyte that

Art Unit: 1641

has the faster dissociation phase, and determining whether the two analytes bind to the same or different binding sites on a ligand by determining (by a label-free detection technique) the influence of the increased concentration on the dissociation phase binding curve profile, wherein a reduced contribution to the dissociation phase binding curve profile for the mixture from the analyte that has the slower dissociation phase indicates that the two analytes bind to the same binding site.

Response to Arguments

Applicants' arguments filed March 5, 2007 have been fully considered and are persuasive. Applicants' amendment to the claims to recite monitoring by a label-free detection technique to determine the dissociation phase of the interaction of the mixture and a reduced contribution to the dissociation phase binding curve profile distinguishes the present claims from the prior art of record. However, the claims should be clarified as indicated above. Also, Applicants should cancel the withdrawn claims to put the application in condition for allowance.

Conclusion

This application is in condition for allowance except for the above formal matters.

Prosecution on the merits is closed in accordance with the practice under Exparte Quayle, 25 USPQ 74, 453 O.G. 213, (Comm'r Pat. 1935).

A shortened statutory period for reply to this action is set to expire **TWO**MONTHS from the mailing date of this letter.

Application/Control Number: 10/722,061 Page 6

Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Y. Lam whose telephone number is 571-272-0822. The examiner can normally be reached on Mon.-Fri. 10-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ANN YEN LAM PATENT EXAMINER